Latest News

Drug Development - Cancer Immunology and Immunotherapy

Six-Month PFS Named Best Endpoint For Phase II Checkpoint Inhibitor Studies

  • 23 Feb 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

Checkpoint inhibitor trials could benefit from using 6-month progression-free survival as the primary endpoint...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Six-Month PFS Named Best Endpoint For Phase II Checkpoint Inhibitor Studies

Anti-Cancer Agents & Biologic Therapy - Drug Development - Cancer in Adolescents - Personalised Medicine

Larotrectinib Benefits Found Across TRK Fusion-Positive Tumour Populations

  • 22 Feb 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

Adults and children with a wide range of tumour types positive for a TRK fusion have responded to larotrectinib therapy...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Larotrectinib Benefits Found Across TRK Fusion-Positive Tumour Populations

Anti-Cancer Agents & Biologic Therapy - Cancer Immunology and Immunotherapy - Renal Cell Cancer

Axitinib–Pembrolizumab ‘Promising’ As Possible First-Line Combination For Advanced RCC

  • 21 Feb 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

Axitinib plus pembrolizumab has shown tolerability and anti-tumour activity for treatment-naïve advanced renal cell carcinoma...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Axitinib–Pembrolizumab ‘Promising’ As Possible First-Line Combination For Advanced RCC

Anti-Cancer Agents & Biologic Therapy - Cancer Aetiology, Epidemiology, Prevention - Cancer Immunology and Immunotherapy - Melanoma and other Skin Tumours

Obesity Paradox Highlighted Among Some Metastatic Melanoma Patients

  • 20 Feb 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

Men undergoing targeted treatment or immunotherapy for metastatic melanoma may have better survival outcomes if they are obese...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Obesity Paradox Highlighted Among Some Metastatic Melanoma Patients

Anti-Cancer Agents & Biologic Therapy - Drug Development - Gastric Cancer

Oral Paclitaxel Noninferior To Intravenous Formulation In Second-Line Advanced Gastric Cancer

  • 19 Feb 2018
  • Author : By Shreeya Nanda, Senior medwireNews Reporter

Korean trial findings indicate that DHP107, an oral form of paclitaxel, has comparable efficacy to the intravenous formulation in patients with unresectable, recurrent or metastatic gastric cancer...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Oral Paclitaxel Noninferior To Intravenous Formulation In Second-Line Advanced Gastric Cancer

Anti-Cancer Agents & Biologic Therapy - Surgery and/or Radiotherapy of Cancer

Regional Hyperthermia Improves Localised Soft Tissue Sarcoma Survival

  • 16 Feb 2018
  • Author : By Shreeya Nanda, Senior medwireNews Reporter

Adding regional hyperthermia to neoadjuvant chemotherapy boosts outcomes in patients with localised high-risk soft tissue sarcoma...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Regional Hyperthermia Improves Localised Soft Tissue Sarcoma Survival

Anti-Cancer Agents & Biologic Therapy - Drug Development - Gastric Cancer

Oral Paclitaxel Noninferior To Intravenous Formulation In Second-Line Advanced Gastric Cancer

  • 19 Feb 2018
  • Author : By Shreeya Nanda, Senior medwireNews Reporter

Korean trial findings indicate that DHP107, an oral form of paclitaxel, has comparable efficacy to the intravenous formulation in patients with unresectable, recurrent or metastatic gastric cancer...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Oral Paclitaxel Noninferior To Intravenous Formulation In Second-Line Advanced Gastric Cancer

Anti-Cancer Agents & Biologic Therapy - Breast Cancer, Metastatic - Geriatric Oncology

Metronomic Chemotherapy Boost To Dual HER2 Blockade Feasible In Older Breast Cancer Patients

  • 15 Feb 2018
  • Author : By Shreeya Nanda, Senior medwireNews Reporter

In older patients with metastatic HER2-positive breast cancer, adding metronomic cyclophosphamide to pertuzumab plus trastuzumab may improve outcomes without worsening toxicity...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Metronomic Chemotherapy Boost To Dual HER2 Blockade Feasible In Older Breast Cancer Patients

Anti-Cancer Agents & Biologic Therapy - Endometrial Cancer - Surgery and/or Radiotherapy of Cancer

Adjuvant Chemoradiotherapy May Be An Option For Certain High-Risk Endometrial Cancer Patients

  • 14 Feb 2018
  • Author : By Shreeya Nanda, Senior medwireNews Reporter

Phase III trial results suggest that the failure-free survival benefit of adjuvant chemoradiotherapy is restricted to women with high-risk stage III endometrial cancer...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Adjuvant Chemoradiotherapy May Be An Option For Certain High-Risk Endometrial Cancer Patients

Cancer Immunology and Immunotherapy - Melanoma and other Skin Tumours - Translational Research

ctDNA Could Serve As Pseudoprogression Biomarker For Immunotherapy-Treated Patients

  • 13 Feb 2018
  • Author : By Shreeya Nanda, Senior medwireNews Reporter

Circulating tumour DNA shows promise as a marker for discriminating pseudoprogression from true progression in patients with stage IV melanoma given PD-1 inhibitors...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof ctDNA Could Serve As Pseudoprogression Biomarker For Immunotherapy-Treated Patients

ESMO E-Learning: Treatment of Locally Advanced NSCLC with Chemo-radiotherapy

New module by Pierre Fournel now available. View the presentation and, if you are an ESMO member, take the CME test!

 

view detailsof

Anti-Cancer Agents & Biologic Therapy - Cervical Cancer - Surgery and/or Radiotherapy of Cancer

Chemoradiotherapy Approach Extends Survival For Stage IIIB Cervical Cancer

  • 12 Feb 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

The addition of cisplatin chemotherapy to radiation significantly improves outcomes for women with stage IIIB squamous cell carcinoma of the uterine cervix...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Chemoradiotherapy Approach Extends Survival For Stage IIIB Cervical Cancer

Anti-Cancer Agents & Biologic Therapy - Prostate Cancer

Apalutamide Extends Metastasis-Free Survival In High-Risk Prostate Cancer

  • 09 Feb 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

SPARTAN study findings support the use of the androgen receptor blocker apalutamide in castration-resistant prostate cancer patients at risk of developing metastases...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Apalutamide Extends Metastasis-Free Survival In High-Risk Prostate Cancer

Anti-Cancer Agents & Biologic Therapy - Drug Development

Early PIK3CA-alpha Inhibitor Findings Suggest Solid Tumour Activity

  • 08 Feb 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

Phase I results indicate that phosphatidylinositol 3-kinase mutated solid tumours may respond to a selective inhibitor...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Early PIK3CA-alpha Inhibitor Findings Suggest Solid Tumour Activity

Anti-Cancer Agents & Biologic Therapy - Prostate Cancer

Chemohormonal Therapy Might Benefit Select Metastatic Prostate Cancer Patients

  • 07 Feb 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

Patients with high-volume metastatic hormone-sensitive prostate cancer have improved overall survival with the addition of docetaxel to androgen deprivation therapy...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Chemohormonal Therapy Might Benefit Select Metastatic Prostate Cancer Patients